Daclizumab + Tacrolimus + Sirolimus

The combination of daclizumab, tacrolimus, and sirolimus is an immunosuppressive regimen that has been studied for use in organ transplantation. This combination has shown efficacy in preventing organ rejection, particularly in renal (kidney) and islet cell transplantation[1][3]. ## Mechanism and Usage This drug combination works through complementary immunosuppressive mechanisms: - **Daclizumab** is a humanized monoclonal antibody that targets the IL-2 receptor (CD25) on activated T cells - **Tacrolimus** is a calcineurin inhibitor that prevents T-cell activation - **Sirolimus** (also known as rapamycin) is a mammalian target of rapamycin (mTOR) inhibitor that blocks cell cycle progression The combination has been studied in various transplant settings, including kidney transplantation, lung transplantation, and islet cell transplantation[1][4]. In renal transplant models, this regimen significantly prolonged allograft survival compared to untreated controls[1]. ## Efficacy and Outcomes In nonhuman primate studies, this combination extended mean renal allograft survival to 36 days versus 7 days in untreated controls[1]. However, significant gastrointestinal toxicity was observed, with four of five treated animals developing fibrinoid vascular necrosis of the small intestine[1]. For lung transplantation, sirolimus plus tacrolimus (without daclizumab) has shown promising results, with better median survival than mycophenolate mofetil (MMF) plus tacrolimus (8.9 years vs. 7.1 years)[4]. The survival improvement was attributed to fewer deaths from chronic rejection, infections, and cancer[4]. ## Administration Considerations Sirolimus is typically not started immediately after transplant surgery because it interferes with wound healing, which could be life-threatening in the initial post-operative period. It is usually initiated 3-12 months after surgery[4]. For optimal efficacy, drug levels need careful monitoring. In some studies, mean trough levels at 2 years post-transplant were 9.1 ng/mL for sirolimus and 8.6 ng/mL for tacrolimus[3]. ## Toxicity and Side Effects The main limitation of this regimen in some studies has been significant gastrointestinal toxicity[1]. The combination may also contribute to nephrotoxicity, which is why some protocols have explored adding budesonide to reduce this effect[2].

Other names

daclizumab, sirolimus, tacrolimusdaclizumab + sirolimus + tacrolimus